Hospital groups are calling for the federal government to take action after Johnson & Johnson warned it will require 340B-eligible providers to pay full price up front for two widely prescribed medications and seek legally required discounts later.

Hospital groups are calling for the federal government to take action after Johnson & Johnson warned it will require 340B-eligible providers to pay full price up front for two widely prescribed medications and seek legally required discounts later.

Hospital groups are calling for the federal government to take action after Johnson & Johnson warned it will require 340B-eligible providers to pay full price up front for two widely prescribed medications and seek legally required discounts later.

Hospital groups are calling for the federal government to take action after Johnson & Johnson warned it will require 340B-eligible providers to pay full price up front for two widely prescribed medications and seek legally required discounts later.

Hospital groups are calling for the federal government to take action after Johnson & Johnson warned it will require 340B-eligible providers to pay full price up front for two widely prescribed medications and seek legally required discounts later.

Hospital groups are calling for the federal government to take action after Johnson & Johnson warned it will require 340B-eligible providers to pay full price up front for two widely prescribed medications and seek legally required discounts later.

Hospital groups are calling for the federal government to take action after Johnson & Johnson warned it will require 340B-eligible providers to pay full price up front for two widely prescribed medications and seek legally required discounts later.

Hospital groups are calling for the federal government to take action after Johnson & Johnson warned it will require 340B-eligible providers to pay full price up front for two widely prescribed medications and seek legally required discounts later.

Four years ago, a team of researchers led by a heavyweight in the field of microbiology made a stunning claim: Cancers have unique microbial signatures that could one day allow tumors to be diagnosed with a blood test. The discovery captured the attention of the scientific community, as well as investors.

State legislatures are taking action to alleviate providers’ prior authorization struggles.